Abstract

G.N. Gildeeva, A.V. Belostotsky, O.V. Gridnev, V.I. Yurkov.

Chronic venous diseases (CVD) of the lower limbs are an acute medical and social problem due to their widespread distribution among a significant part of the population, and patients rarely seek medical help in the early stages of the disease. Medication based on micronized purified flavo¬noid fraction (PMFF) play a leading role in the elimination of CVD symptoms of lo¬wer limbs. The article presents the results of a multi-center open randomized clinical study conducted in Russia on the efficacy and safety (phase III) of the generic drug Trombless® Neo (diosmin+hesperidin) in comparison with the reference product Detralex® with the participation of 130 patients with symptomatic CVD of lower limbs C2-C3 class of the CEAP classification. The results of the study indicate no less efficacy and comparable safety of Trombless® Neo in relation to changes (decrease) in the severity of CVD symptoms after a 60-day course of therapy.